GSK rolls out newest respiratory entrant Nucala; NICE advocates for tailoring diabetes therapy;

@FiercePharma: FDA approves Seqirus' Fluad, the first U.S. adjuvanted flu vaccine. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti. Article | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) has rolled out Nucala, a treatment for patients with a type of severe asthma, in the U.S. Release

> The U.K.'s cost-effectiveness gatekeepers are advocating for a tailored approach to Type 2 diabetes treatment. More

> Negative news about the risks or side effects of statin drugs prompts people to ratchet back their use of the drug, increasing risks of heart attacks and strokes, a new study found. Report

> Horizon Pharma ($HZNP) nabbed European approval for Ravicti, its new add-on drug for urea cycle disorders. Report

> The market for opioid-induced constipation treatments will swell to $650M by 2019, research and consulting firm GlobalData predicts. More

Medical Device News

@FierceMedDev: ICYMI yesterday: Boston Sci receives FDA and CE mark approval of its thrombectomy catheter for deep vein thrombosis. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. Article | Follow @VarunSaxena2

@EmilyWFierce: $GILD: "Let's not fold to advocacy pressure in 2014." More from the WSJ | Follow @EmilyWFierce

> Syneron Medical bogged down with slumping sales for ultrasound fat-zapping device. Story

> Theranos asked military general for help tamping down 'misinformation' from the DOD. Article

Biotech News

@FierceBiotech: Q&A: Philips on what's next after the first year of HealthTech. More from FierceMedicalDevices | Follow @FierceBiotech

@JohnCFierce: Zafgen shares crash after second patient in pivotal obesity study dies. Report | Follow @JohnCFierce

@DamianFierce: Knicks Porzingis jersey not yet for sale so I'm just getting his name tattooed on my back as a placeholder. | Follow @DamianFierce

> Boehringer joins MD Anderson's cadre of cancer collaborators with pancreatic partnership. Report

> Ex-GSK cancer chief Paoletti scores $29M war chest for multiple myeloma startup Kesios. Article

> Outsmarting tumors: Biotech startup maestro Heyman fuels ORIC with $53M round. More

> MedDay misses endpoint in PhIII multiple sclerosis vision loss trial. Story

Biotech Research News

> UCLA scientist points to pregnancy hormone as a safe, simple MS therapy. Article

> Scripps team partially corrects impact of a cystic fibrosis mutation. More

> Rockefeller researchers study a new approach to controlling nicotine addiction. Story

> BRCA1 is back in the spotlight, this time for Alzheimer's disease. Report

> New class of antimicrobials may be highly potent against MRSA. Article

Vaccines News

> Parents may be misled by inaccurate HPV vaccine websites, report says. Item

> NIAID to bring Chikungunya vaccine into Phase II. Report

> Valneva's C. diff vaccine found to be 'highly immunogenic' in PhII. Article

> Sanofi, Shantha to supply polio vaccines for India's universal immunization scheme. More

> FDA approves Seqirus' Fluad, the first U.S. boosted flu vaccine. Story

Pharma Marketing News

> Novo Nordisk strikes back with SGLT2-beating data on Victoza. Story

> Study finds no shortage of misleading HPV vaccine websites. Item

> Amgen biosim advances toward battle with AbbVie's mega-selling Humira. Report

> Pfizergan headed for top of ad-spend leaderboard--and not just in pharma. Article

> Ex-Sanofi staffer adds new allegations to last year's kickback suit. More

And Finally... Forget Adderall for a workplace boost; some Silicon Valley workers are reportedly taking small doses of the psychedelic drug LSD to make themselves more productive. Report

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.